Cargando…

P46 SEER-MEDICARE DATABASE: REAL-WORLD TREATMENTS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED MULTIPLE MYELOMA TREATED WITH 1–3 PRIOR LINES OF THERAPY, INCLUDING A PI AND IMID

Detalles Bibliográficos
Autores principales:	Einsele, H., Dhakal, B., Potluri, R., Schecter, J., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Nair, S., He, J., Voelker, J., Cost, P., Valluri, S., Yalniz, F., Pacaud, L., Yong, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Poster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171602/ http://dx.doi.org/10.1097/01.HS9.0000936312.94801.44

Ejemplares similares

P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE
por: Dhakal, B., et al.
Publicado: (2022)

P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY
por: Einsele, H., et al.
Publicado: (2023)

S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
por: Einsele, Hermann, et al.
Publicado: (2023)

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
por: Bartlett, J B, et al.
Publicado: (2005)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
por: Suzuki, Kazuhito, et al.
Publicado: (2023)

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA
por: Hillengass, J., et al.
Publicado: (2022)

Comparison of SEER Treatment Data With Medicare Claims
por: Noone, Anne-Michelle, et al.
Publicado: (2016)

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
por: Einsele, H, et al.
Publicado: (2022)

IMID-Biobank: Biobank of immune-mediated inflammatory diseases (IMIDs)
por: Marsal, S, et al.
Publicado: (2010)

Opportunities for Personalizing Colorectal Cancer Care: An Analysis of SEER-Medicare Data
por: Rivers, Zachary T., et al.
Publicado: (2022)

Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study
por: Shen, C., et al.
Publicado: (2018)

Overview of the SEER—Medicare Health Outcomes Survey Linked Dataset
por: Ambs, Anita, et al.
Publicado: (2008)

Hepatocellular Carcinoma Survival by Etiology: A SEER‐Medicare Database Analysis
por: Brar, Gagandeep, et al.
Publicado: (2020)

Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis
por: Scarton, Lisa, et al.
Publicado: (2022)

GWAS in IMIDs
por: Plenge, R M
Publicado: (2010)

Racial Disparities in Breast Cancer Treatments and Adverse Events in the SEER-Medicare Data
por: Wieder, Robert, et al.
Publicado: (2023)

Using Pointwise Mutual Information for Breast Cancer Health Disparities Research With SEER-Medicare Claims
por: Egleston, Brian L., et al.
Publicado: (2023)

Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
por: Jung, Yoo Jin, et al.
Publicado: (2021)

Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods
por: Aly, Abdalla, et al.
Publicado: (2015)

Trends in Sociodemographic Disparities in Colorectal Cancer Staging and Survival: A SEER–Medicare Analysis
por: Liang, Peter S., et al.
Publicado: (2020)

Prediagnostic CT or MRI Utilization and Outcomes in Hepatocellular Carcinoma: SEER-Medicare Database Analysis
por: Karim, Mohammad A., et al.
Publicado: (2023)

Adjuvant treatment for the elderly patient with resected gallbladder cancer: a SEER-Medicare analysis
por: de Savornin Lohman, Elise, et al.
Publicado: (2022)

Base‐Assisted Imidization: A Synthetic Method for the Introduction of Bulky Imide Substituents to Control Packing and Optical Properties of Naphthalene and Perylene Imides
por: Mahl, Magnus, et al.
Publicado: (2020)

Health-care access dimensions and ovarian cancer survival: SEER-Medicare analysis of the ORCHiD study
por: Montes de Oca, Mary Katherine, et al.
Publicado: (2023)

P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Broijl, A., et al.
Publicado: (2023)

Treatment practice in the elderly patient with chronic lymphocytic leukemia—analysis of the combined SEER and Medicare database
por: Satram-Hoang, Sacha, et al.
Publicado: (2014)

Hemochromatosis, Iron Overload–Related Diseases, and Pancreatic Cancer Risk in the Surveillance, Epidemiology, and End Results (SEER)-Medicare
por: Julián-Serrano, Sachelly, et al.
Publicado: (2021)

Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis
por: Sadetsky, Natalia, et al.
Publicado: (2020)

The Association of Statin Use after Cancer Diagnosis with Survival in Pancreatic Cancer Patients: A SEER-Medicare Analysis
por: Jeon, Christie Y., et al.
Publicado: (2015)

Mechanochemical N-alkylation of imides
por: Briš, Anamarija, et al.
Publicado: (2017)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Long term survival with thoracoscopic versus open lobectomy: propensity matched comparative analysis using SEER-Medicare database
por: Paul, Subroto, et al.
Publicado: (2014)

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER‐medicare analysis
por: Ailawadhi, Sikander, et al.
Publicado: (2017)

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare
por: Petrick, Jessica L., et al.
Publicado: (2017)

SUN-626 Survival of Patients with Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus in a Seer-Medicare Cohort
por: Thapi, Sahityasri, et al.
Publicado: (2020)

Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis
por: Bishnoi, Rohit, et al.
Publicado: (2020)

Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER‐Medicare analysis
por: Ades, Steven, et al.
Publicado: (2022)

Lack of survival advantage among re-resected elderly glioblastoma patients: a SEER-Medicare study
por: Goldman, Debra A, et al.
Publicado: (2020)

Disparities in cancer-specific and overall survival in black women with endometrial cancer: A Medicare-SEER study
por: Saris, Daniel H., et al.
Publicado: (2022)

The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies
por: Crawford, Rebecca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5k86j37a10367f7sf5skg219pi